In a 1st for US, its FDA appoves at-home use of nasal flu vaccine; India’s version yet to gain traction

Massive disease burden 

According to the World Health Organization (WHO), the seasonal flu is an acute respiratory infection caused by influenza viruses. It is common in all parts of the world. And while most people recover without treatment, it causes 3-5 million cases of severe illness, and 290,000 to 650,000 respiratory deaths annually.

There are 4 types of influenza viruses—types A, B, C and D. Influenza A and B viruses circulate and cause seasonal epidemics of disease.

India experiences two peaks of seasonal influenza each year, one between January and March, and another during the post-monsoon season. Dr Sourabh Pahuja, senior consultant, pulmonary medicine, at Amrita Hospital, Faridabad, notes that annual vaccines can reduce the risk of flu by 50-60 percent.

The United Nations health body recommends annual flu vaccinations for pregnant women, children aged 6 months to 5 years, people over 65, those with chronic medical conditions, and healthcare workers.

In India, though, the flu vaccine is not included in the government’s Universal Immunization Programme. With each dose costing between Rs 2,000 and Rs 2,500, this high price is a major factor deterring many from getting vaccinated.

According to the Indian Academy of Pediatrics (IAP)—the largest network of paediatricians in the country—flu vaccines should be taken annually by kids aged between six months and 5 years and those with high-risk conditions.

But in India, the uptake of flu vaccine among children as well as those above the age of 45 has traditionally been low. For example, the Longitudinal Ageing Study in India, a national household survey conducted during 2017–2018, showed that only 1.5 percent of adults aged 45 or above were vaccinated against influenza.

Status of India’s first nasal flu vaccine

Launched in India in November last year, Nasovac S4 is a live quadrivalent influenza vaccine containing four influenza vaccine virus strains, aligning with WHO recommendations, but a dose of 0.5 ml is administered via a syringe and a spray device supplied with the vaccine.

Priced at Rs 1,590 per dose, Nasovac S4 includes two influenza Type A virus strains (A/H1N1 and A/H3N2) and two influenza Type B virus strains (Victoria and Yamagata lineage).

Recommended for individuals above the age of 2, Nasovac S4 actively immunises against influenza disease caused by these virus strains. This nasal spray flu vaccine works by initiating its action in the nasal passages, stimulating the immune system to produce antibodies against the infection.

But Dr Pahuja pointed out that, in India, patients are not yet opting for the nasal vaccine because its indications are very selective. “The availability of this vaccine is also a major concern, as it is a live-attenuated vaccine (which uses a weakened form of the virus to stimulate an immune response),” he said.

The pulmonologist also added that those who take influenza shots still opt for the inactivated vaccine (that contains the killed virus), which is more widely available.

“We can say that the acceptability of the nasal vaccine is not high at present, but with more data emerging in the future, as well as the convenience of its use, it is likely that more people will accept it in due course,” he said.

Dr Vikas Mittal, pulmonologist with CK Birla Hospital in Delhi, too, underlined that nasal influenza vaccine is a recent launch and is yet to become widely available in pharmacies or introduced to doctors.

ThPrint reached SII via email for sale details of Nasovac S4. This report will be updated if and when a response is received.

A spokesperson for Myab, however, replied saying that “The response (to the nasal vaccine) has been great. Acceptance in the paediatric and geriatric segment has been great. Ease and convenience of a needle free vaccine is gaining interest among doctors and patients.”

The company, however, did not share how many doses of the vaccine have been administered in the country so far.

FOLLOW US ON GOOGLE NEWS

Read original article here

Denial of responsibility! Todays Chronic is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – todayschronic.com. The content will be deleted within 24 hours.

Leave a Comment